Godói Isabella Piassi, Lemos Livia Lovato Pires, de Araújo Vânia Eloisa, Bonoto Braúlio Cesar, Godman Brian, Guerra Júnior Augusto Afonso
Programa de Pós-graduação em Medicamentos e Assistência Farmacêutica, sala 1023, Faculdade de Farmácia, Universidade Federal de Minas Gerais, Av. Presidente Antônio Carlos, 6627, Campus Pampulha, Belo Horizonte, Minas Gerais, CEP 31270-901, Brazil.
SUS Collaborating Centre for Technology Assessment & Excellence in Health, sala 1042, Faculdade de Farmácia, Universidade Federal de Minas Gerais, Av. Presidente Antônio Carlos, 6627, Campus Pampulha, Belo Horizonte, Minas Gerais, CEP 31270-901, Brazil.
J Comp Eff Res. 2017 Mar;6(2):165-180. doi: 10.2217/cer-2016-0045. Epub 2017 Jan 13.
Dengue virus (DENV) is a serious global health problem. CYD-TDC (Dengvaxia) was the first vaccine to gain regulatory approval to try and address this problem.
Summarize all available evidence on the immunogenicity, efficacy and safety of the CYD-TDV dengue vaccine.
Meta-analysis and systematic review.
The best and worst immunogenicity results were for DENV4 and DENV1, respectively. Vaccine efficacy of 60% was derived from studies with participants aged 2-16 years old, with DENV4 and DENV2 presenting the best and worst results, respectively. Erythema and swelling were more frequent with CYD-TDV. No differences were detected for systemic adverse events.
CYD-TDV showed moderate efficacy in children and adolescents. From the immunogenicity results in adults, we can expect satisfactory efficacy from vaccination in this population.
登革病毒（DENV）是一个严重的全球健康问题。CYD-TDC（登革热疫苗）是首个获得监管批准以试图解决这一问题的疫苗。
总结关于CYD-TDV登革热疫苗免疫原性、有效性和安全性的所有现有证据。
荟萃分析和系统评价。
免疫原性最佳和最差的结果分别针对DENV4和DENV1。60%的疫苗效力来自对2至16岁参与者的研究，其中DENV4和DENV2分别呈现最佳和最差结果。CYD-TDV导致的红斑和肿胀更为常见。全身不良事件未发现差异。
CYD-TDV在儿童和青少年中显示出中等效力。从成人的免疫原性结果来看，我们可以预期该疫苗在这一人群中接种会产生令人满意的效力。
